Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2013
The characterisation and risk factors of ischaemic heart disease in patients with coeliac disease.
Studies have shown an increased risk of ischaemic heart disease (IHD) in patients with coeliac disease (CD), despite the patients' lack of traditional IHD risk factors. ⋯ Despite evidence of an increased risk of IHD and higher cardiovascular mortality, patients with coeliac disease with IHD have a more favourable cardiac risk profile compared with IHD in reference individuals.
-
Aliment. Pharmacol. Ther. · Apr 2013
Randomized Controlled Trial Comparative StudyRandomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. ⋯ When combined with mesalazine enema, prolonged-release mesalazine once-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis (Clinicaltrials.gov: NCT00737789).
-
Aliment. Pharmacol. Ther. · Apr 2013
The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
Assessment of both GI and CV risks vs. the benefits of low-dose aspirin for individual patients can be difficult in clinical practice. ⋯ There are many clinical situations where the number of potential upper GI complications induced by low-dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.